Company Filing History:
Years Active: 2019
Title: The Innovative Contributions of Federica Cruciani in Pharmaceutical Science
Introduction: Federica Cruciani, a prominent inventor based in Bologna, Italy, has made significant strides in the field of pharmaceutical compositions. Her innovative work focuses on the development of effective treatments for vaginal infections, specifically targeting bacterial vaginosis through her groundbreaking patent.
Latest Patents: Federica holds one patent that details her pharmaceutical compositions comprising rifaximin. This invention relates to the effective treatment of vaginal infections by utilizing rifaximin granules that are designed to release the active ingredient in a controlled manner within the vagina. The patent outlines not only the composition but also the processes for preparing these pharmaceutical formulations, as well as effective dosages and treatment regimens to aid recovery and prevent relapse.
Career Highlights: As an inventor at Alfasigma S.p.A., Federica Cruciani has dedicated her career to advancing pharmaceutical science. Her contributions have played a pivotal role in enhancing the treatment options available for individuals suffering from vaginal infections, showcasing her commitment to improving patient care through innovative research.
Collaborations: Throughout her career, Federica has worked alongside esteemed colleagues including Giuseppe Claudio Viscomi and Paola Maffei. These collaborations have fostered a synergetic environment that encourages the sharing of knowledge and further development of groundbreaking pharmaceutical technologies.
Conclusion: Federica Cruciani’s pioneering work in the field of pharmaceutical compositions significantly contributes to the treatment landscape of vaginal infections. Her dedication to innovation not only enhances existing therapeutic options but also underscores the importance of ongoing research in tackling women’s health issues. With one patent to her name and a commitment to excellence, Federica represents the forefront of pharmaceutical innovation.